How soon does appetite change?

The reported experience is a spread rather than a fixed point — some people notice reduced appetite in the first four weeks, others take longer. The effect strengthens as the dose is escalated (0.25 up to 2.4 mg), and because semaglutide's roughly one-week half-life means each step takes about five weeks to reach steady state, appetite effects tend to build with the dose rather than appearing fully at the start.

How long does the weight loss keep going?

The STEP data shows a long build and a long maintenance tail. STEP 1 reached a mean ~15% loss at 68 weeks, and STEP 5 showed ~15.6% at week 52 holding to ~15.2% at week 104 — so the curve reaches most of its effect over the first year and then is well maintained into a second year rather than reversing. Greater loss was seen when paired with structured lifestyle intervention.

Is semaglutide approved for human use?

Semaglutide is an FDA-approved drug, but Titan does not supply it, and research-grade material is not a substitute for a prescribed medicine. Titan Peptide Lab supplies retatrutide strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption. The timeline data here summarises published clinical research and is not medical or dosing advice.

Semaglutide · time-to-effect · research use only

How long does semaglutide take to work? What the STEP trials actually show.

The honest answer has two parts on two clocks. The fast clock is appetite: semaglutide's effect on satiety and food intake can appear early — some notice reduced appetite within the first few weeks — but it is neither immediate nor uniform, because the drug is titrated slowly over months and its ~1-week half-life means each dose approaches steady state over roughly five weeks. The slow clock is body weight, which builds across the entire trial window: STEP 1 reported a mean loss of about 15% of body weight at 68 weeks, and STEP 5 showed the curve still climbing out to 104 weeks. This page reproduces that trajectory as a research reference — why the early weeks are titration and appetite, why the meaningful weight curve is measured in months to a year, and how the timeline compares with the triple agonist Titan stocks, retatrutide. It is a summary of clinical-trial data, not a human-use protocol or medical advice.

Retatrutide (triple agonist) — $199.99 Retatrutide vs semaglutide

Appetite is the early clock — but it's gradual

Semaglutide reduces appetite and increases satiety by acting on GLP-1 receptors, and some people report reduced hunger within the first weeks. But it is not an on/off switch: the drug is escalated slowly (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over months), and the appetite effect strengthens as the dose climbs. The published experience is a spread — some notice appetite changes in the first four weeks, others take longer — so 'the first weeks' is where appetite starts, not where results land.

The escalation ladder →

Why the half-life shapes the ramp

Semaglutide has roughly a one-week (about 165-hour) half-life — the longest of the common incretin peptides. That means each dose takes roughly five weeks to approach steady state, which is exactly why the titration steps are spaced weeks apart rather than days. The slow pharmacokinetics are not a limitation to work around; they are the reason the timeline is inherently a multi-month process, and why the trials never expected fast results.

Retatrutide timeline →

The weight curve builds over 68 weeks

The headline STEP 1 result: a mean weight loss of about 15% of baseline at 68 weeks on semaglutide 2.4 mg, versus about 2.4% on placebo — with the curve descending steadily across the full window rather than plateauing early. Greater loss was seen when medication was paired with structured lifestyle intervention. The meaningful timeline for weight change is measured in months to a year, not weeks, and that is what the trials were designed around.

Semaglutide side effects →

It keeps building past a year

STEP 5 extended the picture: participants lost a mean 15.6% at week 52 and were still at 15.2% at week 104, showing the effect is well maintained from roughly one to two years rather than reversing. The 104-week losses landed within half a percentage point of the 68-week STEP 1 figures. So the 'how long' answer has a long tail: the curve reaches its bulk over the first year and then holds, rather than being a short course.

Retatrutide vs semaglutide →

How the timeline compares with retatrutide

Retatrutide — the compound Titan stocks — is a triple agonist (GLP-1 / GIP / glucagon) and its Phase 2 data showed a steeper early trajectory than a single-receptor GLP-1 agonist, though it too is titrated over months. Semaglutide is the clean single-receptor reference for the shape of the curve: slow ramp, months-long build, long maintenance tail. Reading it makes the triple agonist's timeline easier to interpret. Titan does not sell semaglutide; it is referenced here only as the comparator.

Retatrutide titration →

Research-use framing

Every figure here comes from the published semaglutide clinical trials (the STEP program) and is reproduced as a research reference for laboratory and in-vitro modelling — not as a prediction of what any individual would experience and not as instructions for human use. Titan does not supply semaglutide; it is referenced only as the single-receptor comparator for the in-stock triple agonist retatrutide, which Titan supplies strictly as a research-use-only reagent, not for human or animal consumption. Nothing here is medical advice.

Research-use policy →

The detail, in plain terms

The time-course, at a glance.

Reference points drawn from the published semaglutide STEP trials (STEP 1, 68 weeks; STEP 5, 104 weeks) plus the drug's pharmacokinetics, reproduced as a research reference. Individual timelines vary; the appetite figures are a reported spread, not a guaranteed schedule. Titan does not stock semaglutide.

Appetite effect: Can begin in the first weeks; reported as a spread — some within ~4 weeks, others longer; strengthens with dose.
Half-life: ~1 week (~165 h) — the longest of the common incretin peptides; ~5 weeks to approach steady state per step.
Titration: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg escalated over months, steps spaced weeks apart because of the long half-life.
Weight loss at 68 weeks: Mean ~15% of baseline on 2.4 mg vs ~2.4% placebo (STEP 1); curve descends across the whole window.
Weight loss at 52 / 104 weeks: ~15.6% at week 52 and ~15.2% at week 104 (STEP 5) — well maintained one-to-two years.
Lifestyle pairing: Greater loss reported when combined with structured lifestyle intervention.
Meaningful timeline: Months to a year for the bulk of weight change, then a long maintenance tail — not a weeks-long course.
vs retatrutide: Triple agonist showed a steeper early trajectory in Phase 2; both titrated over months.

Questions researchers ask

Before you order.

How long does semaglutide take to work?: On two clocks. Appetite suppression can begin within the first weeks for some people, though it is gradual because the dose is titrated up over months. Weight loss is the slow clock: STEP 1 reported a mean ~15% loss at 68 weeks, with the curve building steadily across the whole window. So the bulk of the effect is measured in months to a year, not weeks. These are published trial figures reproduced as a research reference, not medical advice.
How soon does appetite change?: The reported experience is a spread rather than a fixed point — some people notice reduced appetite in the first four weeks, others take longer. The effect strengthens as the dose is escalated (0.25 up to 2.4 mg), and because semaglutide's roughly one-week half-life means each step takes about five weeks to reach steady state, appetite effects tend to build with the dose rather than appearing fully at the start.
How long does the weight loss keep going?: The STEP data shows a long build and a long maintenance tail. STEP 1 reached a mean ~15% loss at 68 weeks, and STEP 5 showed ~15.6% at week 52 holding to ~15.2% at week 104 — so the curve reaches most of its effect over the first year and then is well maintained into a second year rather than reversing. Greater loss was seen when paired with structured lifestyle intervention.
Does semaglutide work faster or slower than retatrutide?: Retatrutide, the triple agonist Titan stocks, showed a steeper early trajectory than a single-receptor GLP-1 agonist in its Phase 2 data, though both are titrated over months. Semaglutide is the clean single-receptor reference for the shape of the curve — slow ramp, months-long build, long maintenance — which makes the triple agonist's timeline easier to read. Titan does not sell semaglutide; it is referenced here only as the comparator.
Is semaglutide approved for human use?: Semaglutide is an FDA-approved drug, but Titan does not supply it, and research-grade material is not a substitute for a prescribed medicine. Titan Peptide Lab supplies retatrutide strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption. The timeline data here summarises published clinical research and is not medical or dosing advice.